Ignite Creation Date:
2025-12-24 @ 12:32 PM
Ignite Modification Date:
2025-12-27 @ 9:36 PM
Study NCT ID:
NCT01449461
Status:
COMPLETED
Last Update Posted:
2021-08-17
First Post:
2011-09-30
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
Sponsor:
Ariad Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-09-20
Start Date Type:
ACTUAL
Primary Completion Date:
2015-11-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-02-18
Completion Date Type:
ACTUAL
First Submit Date:
2011-09-30
First Submit QC Date:
None
Study First Post Date:
2011-10-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-05-26
Results First Submit QC Date:
None
Results First Post Date:
2017-06-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-07-26
Last Update Post Date:
2021-08-17
Last Update Post Date Type:
ACTUAL